Media Articles Related to Coartem (Artemether / Lumefantrine)
Deakin scientists find new way to starve out malaria parasite
Source: Tropical Diseases News From Medical News Today [2017.03.10]
Deakin University scientists have discovered a new way to combat malaria, one of the world's top three infectious disease killers.
Taking aim at a key malaria molecule
Source: Tropical Diseases News From Medical News Today [2017.03.01]
The iron-containing molecule heme is necessary for life. Cells require heme to perform the chemical reactions that produce energy, among other critical tasks.
New malaria vaccine effective in clinical trial
Source: Tropical Diseases News From Medical News Today [2017.02.20]
University of Tübingen researchers in collaboration with the biotech company Sanaria Inc.
Malaria vaccine target's invasion partner uncovered
Source: Tropical Diseases News From Medical News Today [2017.02.13]
A team at the Wellcome Trust Sanger Institute has discovered how a promising malarial vaccine target - the protein RH5 - helps parasites to invade human red blood cells.
Scaled-up malaria control efforts breed insecticide resistance in mosquitoes
Source: Tropical Diseases News From Medical News Today [2017.02.03]
A genetic analysis of mosquito populations in Africa shows that recent successes in controlling malaria through treated bednets has led to widespread insecticide resistance in mosquitoes, according...
Published Studies Related to Coartem (Artemether / Lumefantrine)
Comparative evaluation of efficacy and safety of artesunate-lumefantrine vs.
artemether-lumefantrine fixed-dose combination in the treatment of uncomplicated
Plasmodium falciparum malaria. 
uncomplicated Plasmodium falciparum malaria... CONCLUSION: Artesunate (100 mg)/lumefantrine (480 mg) fixed-dose combination
Intermittent preventive therapy for malaria with monthly artemether-lumefantrine
for the post-discharge management of severe anaemia in children aged 4-59 months
in southern Malawi: a multicentre, randomised, placebo-controlled trial. 
reduced this risk... INTERPRETATION: In areas with intense malaria transmission, chemoprevention with
The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial. [2011.05]
CONCLUSIONS: Subsidizing ACT in the retail sector can significantly increase ACT coverage for reported fevers in rural areas. Further research is needed on the impact and cost-effectiveness of such subsidy programmes at a national scale. TRIAL REGISTRATION: Current Controlled Trials ISRCTN59275137 and Kenya Pharmacy and Poisons Board Ethical Committee for Clinical Trials PPB/ECCT/08/07.
Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine coformulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in Southwest Nigeria. [2011.05]
The therapeutic efficacy and effects of artemether-lumefantrine (AL) and artesunate-amodiaquine co-formulated (AAcf) or co-packaged (AAcp) on malaria-associated anemia (MAA) were evaluated in 285 children < 12 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive one of the three drug combinations...
Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. [2011.04.01]
BACKGROUND: We assessed the efficacy, effectiveness and safety of artemether-lumefantrine, which is the most widely used artemisinin-based combination therapy in Africa, against Plasmodium falciparum malaria during an extended follow-up period after initial and repeated treatment... CONCLUSIONS: Artemether-lumefantrine was highly efficacious even after unsupervised administration, despite significantly lower lumefantrine concentrations, compared with concentration achieved with supervised intake, and was well-tolerated and safe after initial and repeated treatment. CLINICAL TRIAL REGISTRATION: ISRCTN69189899. (c) The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.
Clinical Trials Related to Coartem (Artemether / Lumefantrine)
Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau [Completed]
This study will evaluate the efficacy of treatment with artemether-lumefantrine as compared
to chloroquine in the dose of 50 mg/kg for treatment of malaria in children in
Guinea-Bissau. The genetic basis of the parasites for developing resistance will be
examined. Children coming to one of the Health Centres with symptoms of malaria and a
positive malaria test will be included. The children will be followed weekly until day 70.
In case of reappearance of parasites the child will be re-treated with the opposite study
Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children [Recruiting]
We will test the hypothesis that there is a difference in effectiveness of oral quinine in
comparison to artemether Lumefantrine in the treatment of uncomplicated malaria in children.
Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria [Completed]
Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium
falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK's
Medicines and Healthcare products Regulatory Agency.
CDA is a combination of chlorproguanil, dapsone and artesunate, being developed in a
public-private partnership with the Medicines for Malaria Venture (MMV), World Health
Organisation (WHO-TDR) and academic partners from the London School of Hygiene and Tropical
Medicine, University of Liverpool and the Liverpool School of Tropical Medicine as a
treatment for acute uncomplicated P. falciparum malaria.
The combination of chlorproguanil-dapsone-artesunate (CDA) is being developed to supersede
chlorproguanil-dapsone for the same indication, but the addition of an artemisinin
derivative, artesunate, should provide additional population benefits over
chlorproguanil-dapsone alone. The artemisinins have been demonstrated to rapidly reduce
parasite load and have activity against the sexual stages of the P. falciparum lifecycle. The
addition of a second agent to the chlorproguanil-dapsone combination should also protect
against the selection of resistant strains of P. falciparum.
Artemether-lumefantrine is the only available fixed-dose Artemisinin-based Combination
Therapy actually available and is considered as the gold standard for the treatment of P.
falciparum malaria. This study will therefore aim to demonstrate the non-inferiority of the
combination of CDA to artemether-lumefantrine in terms of efficacy at 28-days. The key
secondary objectives will compare the Parasite Clearance Times (PCT) and the Fever Clearance
Times (FCT) between CDA and artemether-lumefantrine.
Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day [Active, not recruiting]
This is a randomised two arm study, comparing artemether-lumefantrine 3 days and 5 days
treatment. Patients will be randomised in blocks of ten to one of the two treatment arms.
The standard regimen is twice daily for three days with a delay of at least eight hours
between the first and second doses. A single of primaquine will be given to all patients on
the first day of treatment for gametocytocidal activity. The initial treatment will be given
under supervision, all other subsequent doses will be given to the patient to the taken at
home. Patients will be followed up for nine visits over forty two days.
Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria [Recruiting]
Malaria is a protozoan infection transmitted by anopheline mosquitoes. The most severe forms
are caused by Plasmodium (P) falciparum and to a much lesser extent by P. vivax.
Although the interest in research on malaria has increased during the last years, yet little
research is conducted on the "neglected" malaria species P. ovale and P. malariae. P. ovale
being first described in 1922, it still remains unclear whether it displays dormant
pre-erythrocytic liver stages, so called hypnozoites, or not. Primaquine, the only marketed
drug with liver stage activity at present, can cause severe hemolysis in glucose-6-phosphate
dehydrogenase (G6PD) deficient persons and methemoglobinemia. Because G6PD is widely spread
in Central Africa, it is important to explore whether additional intake of liver-active
medication is really needed and on this account further research to investigating new
treatment options with liver stage activity should be conducted.
While, due to widespread resistance, treatment recommendations for P. falciparum and mixed
infections have switched from chloroquine to the safer applicable artemisinin-based
combination therapies (ACTs), World Health Organization (WHO) guidelines still suggest
chloroquine as first line treatment for P. malariae and P. ovale mono infections. Further
studies assessing alternative treatment options are largely missing.
Summing up the current situation for both topics shows the need for further research.
Therefore this study aims to assess the evidence and characterize the frequency of relapses
in P. ovale infections with respect to differences between its subspecies as well as the
effectiveness of the ACT artemether-lumefantrine in P. malariae and P. ovale mono- and mixed
Reports of Suspected Coartem (Artemether / Lumefantrine) Side Effects
Wrong Drug Administered (5),
Acute Respiratory Distress Syndrome (5),
Drug Ineffective (2),
Condition Aggravated (2),
Blood Bilirubin Increased (1),
Abortion Spontaneous (1),
Protein Total Increased (1), more >>